NCT01480284 - Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B Untreated With Nucleic Acid Analogue | Biotech Hunter

Enrollment

166

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

January 31, 2013

Study Completion Date

November 30, 2014

Conditions

Hepatitis B, Chronic

Interventions

DRUG

GSK548470 300 mg tablet

Blue tablets, each tablet containing 300 mg of tenofovir disoproxil fumarate

DRUG

ETV 0.5 mg capsule

Brown capsules, each capsule containing 0.53 mg of entecavir hydrate

Trial Locations (32)

466-8560

GSK Investigational Site, Aichi

467-8602

GSK Investigational Site, Aichi

260-8677

GSK Investigational Site, Chiba

918-8503

GSK Investigational Site, Fukui

803-8505

GSK Investigational Site, Fukuoka

810-8539

GSK Investigational Site, Fukuoka

812-8582

GSK Investigational Site, Fukuoka

820-8505

GSK Investigational Site, Fukuoka

500-8717

GSK Investigational Site, Gifu

734-8530

GSK Investigational Site, Hiroshima

651-2273

GSK Investigational Site, Hyōgo

663-8501

GSK Investigational Site, Hyōgo

760-8557

GSK Investigational Site, Kagawa

890-8520

GSK Investigational Site, Kagoshima

892-8512

GSK Investigational Site, Kagoshima

213-8587

GSK Investigational Site, Kanagawa

862-8655

GSK Investigational Site, Kumamoto

980-8574

GSK Investigational Site, Miyagi

880-0003

GSK Investigational Site, Miyazaki

852-8501

GSK Investigational Site, Nagasaki

856-8562

GSK Investigational Site, Nagasaki

630-8305

GSK Investigational Site, Nara

700-0913

GSK Investigational Site, Okayama

700-8511

GSK Investigational Site, Okayama

540-0006

GSK Investigational Site, Osaka

564-0013

GSK Investigational Site, Osaka